Sleep disorders in Attention-Deficit/ Hyperactivity Disorder (ADHD)
Conditions
Interventions
Trade Name: Methylphenidate ( Ritalin )
Product Name: Methylphenidate
Pharmaceutical Form: Tablet
INN or Proposed INN: METHYLPHENIDATE
CAS Number: 113451
Other descriptive name: Ritalin
Concentration
Sponsors
No Sponsor
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Age 6-12 years Recently diagnosed ADHD Indication for starting with methylphenidate treatment Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: IQ0.1 mg) Contraindications for using methylfenidate Tourette’s syndrome Depression Anxiety disorder Pervasive developmental disorder Psychosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Determine the influence of methylphenidate treatment on sleep-wake rhythm and endogenous melatonin rhythm in children with ADHD.;Secondary Objective: ;Primary end point(s): Primary parameters: 1) sleep latency 2) sleep onset time; 3) total time asleep ( from actigraphy); 4) Difficulty falling asleep (from sleep log) and dim light melatonin onset (DLMO) from salivary melatonin. | — |
Countries
Netherlands
Outcome results
None listed